Pankaj Mohan
Chief Executive Officer bei SONNET BIOTHERAPEUTICS HOLDINGS, INC.
Vermögen: 116 384 $ am 31.03.2024
Profil
Pankaj Mohan was the founder of Outlook Therapeutics, Inc. (founded in 2010) where he served as Director from 2018 to 2019.
He is also the founder of Sonnet BioTherapeutics, Inc. (founded in 2015) where he currently holds the title of Executive Chairman & Chief Executive Officer.
Additionally, Dr. Mohan is the founder of Sonnet BioTherapeutics Holdings, Inc. (founded in 2020) where he currently holds the title of Chairman, President & Chief Executive Officer.
Dr. Mohan's former job experience includes working as Director-Bioprocess Engineering at Genentech, Inc. from 2006 to 2008, Head-Business Operations & Portfolio Management at Bristol Myers Squibb Co. from 2008 to 2010, and Senior Manager at Eli Lilly & Co. from 1993 to 1996.
He also worked as an Assistant Professor at University College London from 1993 to 1996.
Dr. Mohan's education includes a doctorate degree from the University of Birmingham, an undergraduate degree from the Indian Institute of Technology Roorkee, and a graduate degree from Middlesex University Business School.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 11.12.2023 | 62 572 ( 2,04% ) | 116 384 $ | 31.03.2024 |
Aktive Positionen von Pankaj Mohan
| Unternehmen | Position | Beginn |
|---|---|---|
| SONNET BIOTHERAPEUTICS HOLDINGS, INC. | Chief Executive Officer | 01.04.2020 |
Sonnet BioTherapeutics, Inc.
 Sonnet BioTherapeutics, Inc. BiotechnologyHealth Technology SONNET BioTherapeutics, Inc. is a clinical stage biotechnology company, which engages in the development of biologic drugs with single- or bi-specific mechanisms of action. Its pipeline include FHAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and “hitch-hikes” on human serum albumin (HSA) for transport to target tissues. The company was founded by Pankaj Mohan and John K. Cini in 2015 and is headquartered in Princeton, NJ. | Chief Executive Officer | 01.01.2019 |
Ehemalige bekannte Positionen von Pankaj Mohan
| Unternehmen | Position | Ende |
|---|---|---|
| OUTLOOK THERAPEUTICS, INC. | Chief Executive Officer | 18.06.2018 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01.12.2010 |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | 01.05.2008 |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | 02.04.1996 |
| University College London | Corporate Officer/Principal | 01.04.1996 |
Ausbildung von Pankaj Mohan
| University of Birmingham | Doctorate Degree |
| Indian Institute of Technology Roorkee | Undergraduate Degree |
| Middlesex University Business School | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| ELI LILLY AND COMPANY | Health Technology |
| OUTLOOK THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Sonnet BioTherapeutics, Inc.
Sonnet BioTherapeutics, Inc. BiotechnologyHealth Technology SONNET BioTherapeutics, Inc. is a clinical stage biotechnology company, which engages in the development of biologic drugs with single- or bi-specific mechanisms of action. Its pipeline include FHAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and “hitch-hikes” on human serum albumin (HSA) for transport to target tissues. The company was founded by Pankaj Mohan and John K. Cini in 2015 and is headquartered in Princeton, NJ. | Health Technology |
| Sonnet BioTherapeutics Holdings, Inc. |
